IDEAYA Biosciences enrolls first patient in clinical combination trial
- IDEAYA Biosciences advanced its oncology pipeline by dosing the initial patient in a Phase 1/2 study evaluating two targeted therapeutic candidates.
- The clinical evaluation targets specific MTAP-deleted solid tumors, with a primary clinical emphasis on treating pancreatic and non-small cell lung cancer.
- The company initiated a clinical collaboration with Roche and announced a third developmental asset targeting CDKN2A deletions.
IDEAYA Biosciences (NASDAQ:IDYA) enrolled the first patient in its Phase 1/2 clinical trial evaluating the combination of its drug candidates, IDE892 and IDE397, in patients with MTAP-deleted solid tumors.
The clinical program evaluates the therapeutic efficacy of combining a cooperative PRMT5 inhibitor with a MAT2A inhibitor to target metabolic vulnerabilities in non-small cell lung and pancreatic cancers.
The company moved directly to the narrative of its monotherapy progress following these structural additions to its active combination trial pipeline.
The clinical testing of IDE892 demonstrated favorable CYP450 properties across multiple cleared dose cohorts, with no maximum tolerated dose reached by clinical investigators during the initial safety evaluations.
The company stated that the monotherapy expansion portion of the clinical program is anticipated to begin during the third quarter of 2026.
The expanding oncology pipeline is reinforced by a strategic clinical trial collaboration with Roche to assess therapeutic applications across diverse international patient populations.
